Ractigen Therapeutics Begins Phase I Trial of RAG-17 for SOD1-ALS “`
NANTONG and SUZHOU, China, December 24, 2024 — Ractigen Therapeutics, a clinical-stage biopharmaceutical company specializing in RNA-based treatments, today reported that the first patient has been dosed in its Phase I clinical trial of RAG-17. RAG-17 is a novel siRNA therapy targeting Amyotrophic Lateral Sclerosis (ALS) linked to superoxide dismutase…

















